Biosimilar vs. Interchangeable Biosimilar at the Pharmacy

A biosimilar is highly similar to an FDA-approved reference biologic with no clinically meaningful differences in safety, purity, or potency. An interchangeable biosimilar has met additional FDA requirements for interchangeability and may be substituted at the pharmacy without prescriber intervention when state law permits. Interchangeability does not mean it is safer or more effective than another biosimilar.

Biologics are not copied like small-molecule tablets

Many biologic medicines are made using living systems and have complex structures. A biosimilar is highly similar to an FDA-approved reference product, with no clinically meaningful differences in safety, purity, or potency. Because the manufacturing process is complex, a biosimilar is not an exact generic copy in the traditional small-molecule sense. FDA reviews the totality of evidence to determine whether the product meets its approval standard.

Interchangeability is an additional FDA determination

Some biosimilars are approved as interchangeable. That status means the product meets additional requirements related to pharmacy-level substitution under federal law. FDA explains that an interchangeable product may be substituted for its reference product without consulting the prescriber, much like generic substitution, but only subject to applicable state pharmacy law. Not every biosimilar is interchangeable, and companies must seek and support that determination.

It does not mean “better” or “safer”

Interchangeable biosimilars are not considered safer or more effective than other FDA-approved biosimilars. Both biosimilars and interchangeable biosimilars are considered as safe and effective as the reference product for their approved uses. The distinction concerns the substitution pathway, not a higher grade of clinical quality. Avoid telling patients one FDA-approved biosimilar is inferior simply because it lacks interchangeable status.

The state-law layer

State laws may determine whether a pharmacist can substitute, what products qualify, whether the prescriber must be notified, whether the patient must be informed, and what records are kept. These requirements vary. A technician should not independently decide to switch a biologic product based on a wholesaler availability or payer claim. Follow the pharmacy’s state-specific procedure and refer substitution decisions to the pharmacist.

How to verify a product

Confirm the exact prescribed biologic, dosage form, concentration, route, and brand or reference product. FDA’s Purple Book provides licensed biological product information and identifies biosimilar and interchangeable status. Confirm whether the alternative is interchangeable with the specific reference product, then apply state law and the prescription. A product may be a biosimilar to one reference product but cannot be assumed interchangeable with another biologic.

A pharmacy scenario

A prescription names a reference biologic, but the plan prefers a biosimilar. The pharmacy should identify the exact product and determine whether it is FDA-approved as interchangeable with that reference. The pharmacist checks state substitution rules, prescription instructions, patient notification obligations, and whether the product’s device and concentration match. A payer preference alone does not authorize the technician to change the dispensed biologic.

What happens when the prescriber names a biosimilar

A prescriber may prescribe a biosimilar directly; FDA says biosimilars and interchangeable biosimilars can be prescribed in place of a reference product with confidence. If a different product is proposed at dispensing, the pharmacist checks the applicable substitution pathway. Keep the medication record accurate so the actual product received is documented for future reconciliation and adverse-event follow-up.

Exam-level distinction

Remember the relationship: reference product → biosimilar (high similarity and no clinically meaningful differences); interchangeable biosimilar → biosimilar with additional FDA interchangeability determination, with substitution still governed by state law. The word “interchangeable” is not a signal that every biosimilar can be freely switched.

PTCE takeaway

Biosimilars are FDA-approved alternatives to reference biologics. Interchangeability is a specific designation relevant to pharmacy substitution. Check the exact product and state rules, and involve the pharmacist before changing a biologic.

Operational checks that prevent mix-ups

The Purple Book is the FDA database for licensed biological products, including reference products, biosimilars, and interchangeable biosimilars. The product’s FDA status should be checked at the exact product level rather than inferred from a similar brand name. Storage, delivery device, concentration, and administration route also matter: a product with different packaging may require a different handling workflow even when it is an acceptable therapeutic option. State substitution rules may require communication to the prescriber or patient and may set recordkeeping periods. For this reason, staff should route a proposed change through the pharmacist, confirm the prescriber’s intent where required, and document the dispensed product. If a patient asks whether a biosimilar is “the generic,” a plain answer is that it is an FDA-approved highly similar biologic alternative; only a specifically designated interchangeable biosimilar may qualify for pharmacy-level substitution under the state’s rules.

Scope and handoff details

Interchangeability may also be affected by product labeling and state-specific notification requirements. Some states require the pharmacist to notify the prescriber or patient within a defined time or keep a record of the dispensed biologic. Other requirements may differ for products administered in a clinic versus dispensed for home use. A technician can help by checking whether the exact product is in stock, confirming the plan’s requested product, and locating the state procedure, but the clinical and legal substitution decision belongs with the pharmacist. If a patient has a concern about switching, do not describe the products as identical or dismiss the concern. Explain that FDA has reviewed the biosimilar and that the pharmacist can discuss the specific product, device, and state substitution rules.

A useful handoff

For a handoff, include the exact reference and proposed biosimilar names, the prescribed dosage form and route, the payer requirement, and any state-law question. “Same molecule” is not enough information to approve a switch. The Purple Book entry and approved labeling help the pharmacist verify the product relationship and indication.

Points to carry into practice

• Check the current FDA or DEA source and the pharmacy SOP for the exact requirement.
• Hold and escalate an unresolved discrepancy instead of guessing or bypassing a control.